TriLink BioTechnologies, a global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics, under which Quantoom will have access to TriLink’s CleanCap mRNA capping technology for integration in its Ntensify (sa)mRNA production platform to help accelerate the RNA production process and make life-saving therapeutics and vaccines more accessible to patients worldwide. 

TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that improves mRNA yield and process time when compared to legacy capping methods. Under this agreement, TriLink will supply its patented CleanCap technology for use in Quantoom’s (sa)mRNA production platform, allowing customers to benefit from the capping technology to develop their unique (sa)mRNA drugs using the Ntensify platform through clinical development phases.

“Strengthening global health against infectious diseases requires strong industry partnerships,” said Becky Buzzeo, Chief Commercial Officer at Maravai. “We’re excited for the Quantoom production platform to incorporate TriLink’s CleanCap reagents, a proven mRNA capping technology to deliver essential therapeutics and vaccines to nations with limited resources.”

“We are committed to making the RNA technology more accessible and scalable, and this partnership with TriLink is a key step toward that goal,” said José Castillo, CEO of Quantoom Biosciences. “By integrating CleanCap analogs into our platform, we can further empower researchers and manufacturers to develop life-saving vaccines and therapeutics for communities in need.”